Ouchi Takafumi

3 articles in GJC

Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study.

Harris Alon, Ward Caroline L, Rowe-Rendleman Cheryl L, Ouchi Takafumi, Wood Andrew, Fujii Akifumi et al.

J GlaucomaOct 201617 citationsRandomized Controlled Trial

ONO-9054, an EP3/FP agonist, safely lowered IOP dose-dependently in glaucoma/ocular hypertension patients, with effects lasting over 24 hours. This offers a promising new treatment option.

Full abstract PubMed

A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers.

Suto Fumitaka, Rowe-Rendleman Cheryl L, Ouchi Takafumi, Jamil Alam, Wood Andrew, Ward Caroline L

Invest Ophthalmol Vis SciDec 201516 citationsClinical Trial

ONO-9054, a novel dual EP3/FP agonist, was safe and well-tolerated in healthy volunteers, significantly reducing IOP by up to 28%. This supports its potential for glaucoma and ocular hypertension treatment.

Full abstract PubMed

EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study.

Berlin Michael S, Rowe-Rendleman Cheryl, Ahmed Ike, Ross Douglas T, Fujii Akifumi, Ouchi Takafumi et al.

Br J OphthalmolOct 20150 citationsRandomized Controlled Trial

This study found ONO-9054 effectively lowers eye pressure for glaucoma whether given morning or evening, but evening dosing caused slightly more mild redness and dryness.

Full abstract PubMed

All 3 articles loaded

Global Search

Ouchi Takafumi

Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study.

A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers.

EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study.